Cargando…

Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells

Mesenchymal stromal cells (MSCs) have attracted great interest in the field of regenerative medicine. They can home to damaged tissue, where they can exert pro-regenerative and anti-inflammatory properties. These therapeutic effects involve the secretion of growth factors, cytokines, and chemokines....

Descripción completa

Detalles Bibliográficos
Autores principales: Najar, Mehdi, Martel-Pelletier, Johanne, Pelletier, Jean Pierre, Fahmi, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789128/
https://www.ncbi.nlm.nih.gov/pubmed/33505596
http://dx.doi.org/10.4252/wjsc.v12.i12.1474
_version_ 1783633170051104768
author Najar, Mehdi
Martel-Pelletier, Johanne
Pelletier, Jean Pierre
Fahmi, Hassan
author_facet Najar, Mehdi
Martel-Pelletier, Johanne
Pelletier, Jean Pierre
Fahmi, Hassan
author_sort Najar, Mehdi
collection PubMed
description Mesenchymal stromal cells (MSCs) have attracted great interest in the field of regenerative medicine. They can home to damaged tissue, where they can exert pro-regenerative and anti-inflammatory properties. These therapeutic effects involve the secretion of growth factors, cytokines, and chemokines. Moreover, the functions of MSCs could be mediated by extracellular vesicles (EVs) that shuttle various signaling messengers. Although preclinical studies and clinical trials have demonstrated promising therapeutic results, the efficiency and the safety of MSCs need to be improved. After transplantation, MSCs face harsh environmental conditions, which likely dampen their therapeutic efficacy. A possible strategy aiming to improve the survival and therapeutic functions of MSCs needs to be developed. The preconditioning of MSCs ex vivo would strength their capacities by preparing them to survive and to better function in this hostile environment. In this review, we will discuss several preconditioning approaches that may improve the therapeutic capacity of MSCs. As stated above, EVs can recapitulate the beneficial effects of MSCs and may help avoid many risks associated with cell transplantation. As a result, this novel type of cell-free therapy may be safer and more efficient than the whole cell product. We will, therefore, also discuss current knowledge regarding the therapeutic properties of MSC-derived EVs.
format Online
Article
Text
id pubmed-7789128
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-77891282021-01-26 Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells Najar, Mehdi Martel-Pelletier, Johanne Pelletier, Jean Pierre Fahmi, Hassan World J Stem Cells Review Mesenchymal stromal cells (MSCs) have attracted great interest in the field of regenerative medicine. They can home to damaged tissue, where they can exert pro-regenerative and anti-inflammatory properties. These therapeutic effects involve the secretion of growth factors, cytokines, and chemokines. Moreover, the functions of MSCs could be mediated by extracellular vesicles (EVs) that shuttle various signaling messengers. Although preclinical studies and clinical trials have demonstrated promising therapeutic results, the efficiency and the safety of MSCs need to be improved. After transplantation, MSCs face harsh environmental conditions, which likely dampen their therapeutic efficacy. A possible strategy aiming to improve the survival and therapeutic functions of MSCs needs to be developed. The preconditioning of MSCs ex vivo would strength their capacities by preparing them to survive and to better function in this hostile environment. In this review, we will discuss several preconditioning approaches that may improve the therapeutic capacity of MSCs. As stated above, EVs can recapitulate the beneficial effects of MSCs and may help avoid many risks associated with cell transplantation. As a result, this novel type of cell-free therapy may be safer and more efficient than the whole cell product. We will, therefore, also discuss current knowledge regarding the therapeutic properties of MSC-derived EVs. Baishideng Publishing Group Inc 2020-12-26 2020-12-26 /pmc/articles/PMC7789128/ /pubmed/33505596 http://dx.doi.org/10.4252/wjsc.v12.i12.1474 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Najar, Mehdi
Martel-Pelletier, Johanne
Pelletier, Jean Pierre
Fahmi, Hassan
Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells
title Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells
title_full Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells
title_fullStr Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells
title_full_unstemmed Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells
title_short Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells
title_sort novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789128/
https://www.ncbi.nlm.nih.gov/pubmed/33505596
http://dx.doi.org/10.4252/wjsc.v12.i12.1474
work_keys_str_mv AT najarmehdi novelinsightsforimprovingthetherapeuticsafetyandefficiencyofmesenchymalstromalcells
AT martelpelletierjohanne novelinsightsforimprovingthetherapeuticsafetyandefficiencyofmesenchymalstromalcells
AT pelletierjeanpierre novelinsightsforimprovingthetherapeuticsafetyandefficiencyofmesenchymalstromalcells
AT fahmihassan novelinsightsforimprovingthetherapeuticsafetyandefficiencyofmesenchymalstromalcells